22:35 , Jul 19, 2019 |  BioCentury  |  Regulation

A half step forward for heart failure as FDA guidance leaves key question unanswered

A draft FDA guidance for heart failure endpoints could spark investment and accelerate development of cardiovascular therapies. But companies still don’t have a clear sense of when and whether they’ll need to gather mortality data...
12:00 , May 21, 2019 |  BC Extra  |  Financial News

Sequoia leads digital therapeutics company Biofourmis' $35M round

Biofourmis raised $35 million in a series B round to develop its AI-powered digital therapeutics platform for improving patient outcomes. The platform uses AI, drug intervention, wearable sensors and a smartphone app to remotely monitor...